Drug prices & Part D
Medicare's GLP-1 Bridge Offers a 50-Dollar Monthly Pathway to Weight-Loss Drugs Through 2027
A CMS demonstration program launched in July gives eligible Part D enrollees access to Wegovy, Zepbound KwikPen, and Foundayo at a flat 50-dollar monthly copay, with no standard Part D deductible, through December 2027 after a planned longer-term coverage model was postponed indefinitely.
By the Goodsurance editorial teamOctober 11, 2026
CMS launched the Medicare GLP-1 Bridge on July 1, 2026, as a Section 402 demonstration giving eligible Medicare Part D enrollees a flat-rate pathway to three specific weight-loss drugs: Foundayo, Wegovy in injectable and tablet form, and Zepbound KwikPen. The copayment is 50 dollars per month. The standard Part D deductible does not apply.
The bridge was designed as a short-term transition to the BALANCE Model, a broader program that would have folded obesity-drug coverage into standard Part D plan benefits starting in 2027. In April 2026, CMS delayed the Medicare Part D portion of BALANCE indefinitely, saying it needed to gather more utilization data from the bridge before Part D plan sponsors assumed that risk. The bridge was then extended through December 31, 2027.
Eligible Medicare Part D enrollees can access Wegovy or Zepbound for 50 dollars a month through the GLP-1 Bridge, now extended through December 2027.
Manufacturers agreed to provide the three covered drugs at a negotiated net price of 245 dollars per 30-day supply, according to KFF. Because the program operates outside a beneficiary's regular Part D plan, plan sponsors carry no financial risk for bridge-dispensed prescriptions.
Beneficiaries who already receive a GLP-1 through their current Part D formulary do not qualify for the bridge. The standard Low-Income Subsidy that reduces cost-sharing for low-income Part D enrollees does not apply to the 50-dollar bridge copayment.
With the 2027 open enrollment period opening October 15, enrollees who meet the clinical criteria for the bridge should know that switching or enrolling in a new Part D plan during the annual enrollment period will not affect bridge access, as the program runs independently of plan-level coverage.
In plain words
Medicare started a new program on July 1, 2026. It is called the GLP-1 Bridge. It lets some Medicare members get weight-loss drugs for 50 dollars a month. The covered drugs are Wegovy, Zepbound KwikPen, and Foundayo. You must be in a Part D drug plan to qualify. You must also meet health rules about your weight and related conditions. If you already get one of these drugs through your Part D plan, you cannot use the bridge. Low-income drug help does not apply to the 50-dollar cost. The program runs through the end of 2027. Medicare open enrollment starts October 15. Switching your Part D plan during that time will not cut off your bridge access, because the program runs separately from your plan.
Understand the basics first
Source: CMS
Read at the source →